Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Aripiprazole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 20/20 | 1.00 |
| ▸ | HTR1A known ✓ | P08908 | 3/20 | 1.00 |
| ▸ | HTR2A known ✓ | P28223 | 3/20 | 1.00 |
| ▸ | DRD3 | P35462 | 5/20 | 1.00 |
| ▸ | DRD4 | P21917 | 4/20 | 1.00 |
| ▸ | HTR2B | P41595 | 3/20 | 1.00 |
| ▸ | DRD1 | P21728 | 2/20 | 1.00 |
| ▸ | DRD5 | P21918 | 2/20 | 1.00 |
| ▸ | HTR2C | P28335 | 2/20 | 1.00 |
| ▸ | HTR7 | P34969 | 2/20 | 1.00 |
| ▸ | HTR6 | P50406 | 2/20 | 1.00 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | MLNR | O43193 | 1/20 | 1.00 |
| ▸ | HTR3B | O95264 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | ESR1 | P03372 | 1/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aripiprazole SCHEMBL29356997 | 1.00 | DRD2 (1.00) | DRD2DRD3DRD4HTR1AHTR2A | |
| Aripiprazole SCHEMBL8255 | 1.00 | DRD2 (1.00) | DRD2DRD3DRD4HTR1AHTR2A | |
| Aripiprazole SCHEMBL29475637 | 1.00 | DRD2 (1.00) | DRD2DRD3DRD4HTR1AHTR2A | |
| Aripiprazole SCHEMBL29475638 | 1.00 | DRD2 (1.00) | DRD2DRD3DRD4HTR1AHTR2A | |
| Aripiprazole SCHEMBL29438823 | 1.00 | DRD2 (1.00) | DRD2DRD3DRD4HTR1AHTR2A | |
| Aripiprazole SCHEMBL7097505 | 0.99 | DRD2 (0.98) | DRD2DRD3DRD4HTR1AHTR2A | |
| Aripiprazole SCHEMBL236666 | 0.99 | DRD2 (0.98) | DRD2DRD3DRD4HTR1AHTR2A | |
| Aripiprazole SCHEMBL5147095 | 0.99 | DRD2 (0.98) | DRD2DRD3DRD4HTR1AHTR2A | |
| Aripiprazole SCHEMBL30958766 | 0.99 | DRD2 (0.98) | DRD2DRD3DRD4HTR1AHTR2A | |
| Aripiprazole SCHEMBL31174198 | 0.99 | DRD2 (0.98) | DRD2DRD3DRD4HTR1AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102292094-A | Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical | — | 2011-12-21 | — | — | CN | claimed |
| EP-1145711-A1 | Flash-melt oral dosage formulation | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-10-17 | — | — | EP | claimed |
| CN-112451477-B | Pharmaceutical composition comprising sorbitan esters | 奥克梅斯制药爱尔兰有限公司 | 2022-12-30 | — | — | CN | disclosed |
| CN-112451477-A | Pharmaceutical compositions comprising sorbitan esters | 奥克梅斯制药爱尔兰有限公司 | 2021-03-09 | — | — | CN | disclosed |
| CN-107252414-B | Pharmaceutical compositions comprising sorbitan esters | 奥克梅斯制药爱尔兰有限公司 | 2020-11-24 | — | — | CN | disclosed |
| EP-3675838-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | Puretecch LYT, Inc. (US) | 2020-07-08 | — | — | EP | disclosed |
| WO-2019046491-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | ARIYA THERAPEUTICS, INC. (US) | 2019-03-07 | — | — | WO | disclosed |
| US-20150150868-A1 | ARIPIPRAZOLE-ORGANIC ACID COCRYSTAL, PREPARATION OR COMPOSITION CONTAINING SAME, AND PREPARATION METHOD THEREFOR | GCB CO., LTD (KR) | 2015-06-04 | — | — | US | disclosed |
| CN-102008450-B | Drug-cyclodextrin nanoparticles and preparation method thereof | HANGZHOU AIRUISHA BIOLOG MEDICINE TECHNOLOGY CO LTD | 2013-01-30 | — | — | CN | disclosed |
| CN-102008450-A | Drug-cyclodextrin nanoparticles and preparation method thereof | LUWEI ZHAO | 2011-04-13 | — | — | CN | disclosed |
| US-7872132-B2 | Intermediates useful for the preparation of aripiprazole and methods for the preparation of the novel intermediates and aripiprazole | SUVEN LIFE SCIENCES LIMITED (IN) | 2011-01-18 | — | — | US | disclosed |
| EP-1725237-A4 | METHODS FOR TREATING ALCOHOLISM | ALKERMES INC (US) | 2008-08-27 | — | — | EP | disclosed |
| EP-1812395-B1 | METHOD FOR THE PREPARATION OF ARIPIPRAZOLE, AND CORRESPONDING INTERMEDIATES AND THEIR PREPARATION | SUVEN LIFE SCIENCES LTD (IN) | 2008-05-21 | — | — | EP | disclosed |
| EP-1758600-A4 | METHODS AND COMPOSITIONS FOR TREATING MOOD DISORDER | MOOD MAN SCIENCES LLC (US) | 2008-03-05 | — | — | EP | disclosed |
| EP-1812395-A1 | METHOD FOR THE PREPARATION OF ARIPIPRAZOLE, AND CORRESPONDING INTERMEDIATES AND THEIR PREPARATION | Suven Life Sciences Limited (IN) | 2007-08-01 | — | — | EP | disclosed |
| EP-1758600-A1 | METHODS AND COMPOSITIONS FOR TREATING MOOD DISORDER | Mood Management Sciences, LLC (US) | 2007-03-07 | — | — | EP | disclosed |
| EP-1725237-A2 | METHODS FOR TREATING ALCOHOLISM | Alkermes Controlled Therapeutic, II (US) | 2006-11-29 | — | — | EP | disclosed |
| WO-2006038220-A1 | NOVEL INTERMEDIATES USEFUL FOR THE PREPARATION OF ARIPIPRAZOLE AND METHODS FOR THE PREPARATION OF THE NOVEL INTERMEDIATES AND ARIPIPRAZOLE | SUVEN LIFE SCIENCES LIMITED (IN) | 2006-04-13 | — | — | WO | disclosed |
| WO-2005120523-A1 | METHODS AND COMPOSITIONS FOR TREATING MOOD DISORDER | MOOD MANAGEMENT SCIENCES, LLC (US) | 2005-12-22 | — | — | WO | disclosed |
| WO-2005089486-A2 | METHODS FOR TREATING ALCOHOLISM | ALKERMES CONTROLLED THERAPEUTIC, II (US) | 2005-09-29 | — | — | WO | disclosed |